Exodus Point Capital Management, LP Provention Bio, Inc. Transaction History

Exodus Point Capital Management, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	BUY	$6.7 - $24.21 $126,341 - $456,527	18,857 New	18,857 $454,000
Q2 2022 Aug 19, 2022	SELL	$3.65 - $7.3 $45,625 - $91,250	-12,500 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$3.4 - $7.88 $5,905 - $13,687	-1,737 Reduced 12.2%	12,500 $92,000
Q4 2021 Feb 11, 2022	SELL	$5.59 - $7.39 $81,893 - $108,263	-14,650 Reduced 50.71%	14,237 $80,000
Q3 2021 Nov 15, 2021	SELL	$5.66 - $8.33 $73,874 - $108,723	-13,052 Reduced 31.12%	28,887 $185,000
Q2 2021 Aug 16, 2021	BUY	$6.71 - $11.04 $281,410 - $463,006	41,939 New	41,939 $354,000
Q3 2020 Nov 16, 2020	SELL	$10.34 - $15.2 $419,886 - $617,241	-40,608 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$7.81 - $17.0 $181,168 - $394,349	23,197 Added 133.23%	40,608 $573,000
Q1 2020 May 15, 2020	SELL	$5.42 - $17.75 $558,368 - $1.83 Million	-103,020 Reduced 85.54%	17,411 $160,000
Q4 2019 Feb 14, 2020	BUY	$5.84 - $14.9 $573,085 - $1.46 Million	98,131 Added 440.05%	120,431 $1.79 Million
Q3 2019 Nov 14, 2019	BUY	$6.83 - $13.0 $152,309 - $289,900	22,300 New	22,300 $152,000

170K

Ticker PRVB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,549,904
Description
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.